Washington D.c., DC18 Active Studies

Heart Attack Clinical Trials in Washington D.c., DC

Find 18 actively recruiting heart attack clinical trials in Washington D.c., DC. Connect with local research sites and explore new treatment options.

18
Active Trials
15
Sponsors
4,246
Enrolling

Recruiting Heart Attack Studies in Washington D.c.

RecruitingWashington D.c., DCNCT04262466

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a fi...

727 participants
Immunocore Ltd
View Study Details
RecruitingWashington D.c., DCNCT06073821

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

The main objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia (CLL)...

652 participants
BeiGene
View Study Details
RecruitingWashington D.c., DCNCT05156398

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to \<18 years with episodic migraine....

640 participants
Pfizer
View Study Details
RecruitingWashington D.c., DCNCT06001918

Nectero EAST System Clinical Study

The purpose of this randomized clinical trial is to treat patients with small to mid-sized abdominal aortic aneurysms (AAA), maximum diameter of 3.5 cm to 5.0 cm, using a locally delivered, single-dos...

400 participants
Nectero Medical, Inc.
View Study Details
RecruitingWashington D.c., DCNCT07122193

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States

The purpose of this study is to assess the safety and efficacy of NT 201 compared with placebo in participants with moderate to severe platysma prominence. The study will be conducted in two periods: ...

300 participants
Merz North America, Inc.
View Study Details
RecruitingWashington D.c., DCNCT05878717

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

This study investigates the efficacy and safety of belimumab compared to placebo, in addition to standard therapy, for the treatment of participants with systemic sclerosis associated interstitial lun...

300 participants
GlaxoSmithKline
View Study Details
RecruitingWashington D.c., DCNCT04965675

A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine....

285 participants
H. Lundbeck A/S
View Study Details
RecruitingWashington D.c., DCNCT06124157

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-cl...

222 participants
National Cancer Institute (NCI)
View Study Details
RecruitingWashington D.c., DCNCT06317662

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangem...

153 participants
National Cancer Institute (NCI)
View Study Details
RecruitingWashington D.c., DCNCT05952037

A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia

This study will evaluate the safety and efficacy of the BCL2 inhibitor sonrotoclax (BGB-11417) in participants with relapsed/refractory Waldenström's Macroglobulinemia (R/R WM) and in combination with...

105 participants
BeiGene
View Study Details
RecruitingWashington D.c., DCNCT02323399

Study to Determine the Pharmacokinetics and Pharmacodynamic Effects of Phenylephrine on BP Via IV

The primary objective of this study is to evaluate the dose effect of Phenylephrine Hydrochloride Injection on the treatment of clinically relevant decreased blood pressure in the pediatric population...

100 participants
West-Ward Pharmaceutical
View Study Details
RecruitingWashington D.c., DCNCT05835310

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

A Study to evaluate the PK, PD, efficacy, and safety of Anifrolumab in children with moderate to severe active SLE...

100 participants
AstraZeneca
View Study Details
RecruitingWashington D.c., DCNCT05955261

A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

This is a phase 2 study to test the hypothesis that venetoclax in combination with standard chemotherapy will be tolerable and active in pediatric patients with newly diagnosed acute myeloid leukemia ...

70 participants
St. Jude Children's Research Hospital
View Study Details
RecruitingWashington D.c., DCNCT05849662

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will re...

58 participants
Therapeutic Advances in Childhood Leukemia Consortium
View Study Details
RecruitingWashington D.c., DCNCT04889430

Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy

The purpose of this Phase 3 study is to determine whether iptacopan (LNP023) is efficacious and safe for the treatment of aHUS in adult patients who are treatment naive to complement inhibitor therapy...

50 participants
Novartis Pharmaceuticals
View Study Details
RecruitingWashington D.c., DCNCT04571138

A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma

Patients with relapsed or refractory leukemia or lymphoma are often refractory to further chemotherapy. In this study, the investigators will attempt to use T cells obtained directly from the patient,...

42 participants
Seattle Children's Hospital
View Study Details
RecruitingWashington D.c., DCNCT04990102

Phase IB/II of CPX-351 for Relapse Prevention in AML

This is a phase IB/II study with a 3+3 dose de-escalation study design. Patients will continue maintenance treatment with CPX-351 for 6 cycles on D1 and D3, as long as patient remains in CR. The dose ...

24 participants
Georgetown University
View Study Details
RecruitingWashington D.c., DCNCT06248515

A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors

The goal of this clinical trial is to study the effect of sacituzumab govitecan-hziy in adult patients with advanced thymoma and thymic carcinoma after progressing on at least one prior line of therap...

18 participants
Georgetown University
View Study Details

About Heart Attack Clinical Trials in Washington D.c.

A heart attack (myocardial infarction) occurs when blood flow to part of the heart muscle is blocked, usually by a blood clot. It is a medical emergency requiring immediate treatment. Long-term management includes medications, lifestyle changes, and cardiac rehabilitation.

There are currently 18 heart attack clinical trials recruiting participants in Washington D.c., DC. These studies are seeking a combined 4,246 participants. Research is being sponsored by Immunocore Ltd, BeiGene, Pfizer and 12 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Heart Attack Clinical Trials in Washington D.c. — FAQ

Are there heart attack clinical trials in Washington D.c.?

Yes, there are 18 heart attack clinical trials currently recruiting in Washington D.c., DC. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Washington D.c.?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Washington D.c. research site will contact you about next steps.

Are clinical trials in Washington D.c. free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Washington D.c. studies also compensate for your time and travel.

What heart attack treatments are being tested?

The 18 active trials in Washington D.c. are testing new therapies including novel drugs, biologics, and treatment approaches for heart attack.

Data updated March 2, 2026 from ClinicalTrials.gov